- Home
- MIRM vs SRAD Comparison
MIRM vs SRAD Comparison
Compare MIRM & SRAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | SRAD |
|---|---|---|
| Founded | 2018 | 2001 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.0B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MIRM | SRAD |
|---|---|---|
| Price | $101.26 | $13.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 16 |
| Target Price | ★ $119.85 | $24.31 |
| AVG Volume (30 Days) | 1.0M | ★ 2.7M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.59 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,138,000.00 | N/A |
| Revenue This Year | $26.22 | $24.03 |
| Revenue Next Year | $22.04 | $14.81 |
| P/E Ratio | ★ N/A | $49.48 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $43.50 | $11.66 |
| 52 Week High | $114.99 | $32.22 |
Technical Indicators
Market Signals| Indicator | MIRM | SRAD |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 45.44 |
| Support Level | $95.68 | $11.84 |
| Resistance Level | $107.51 | $13.73 |
| Average True Range (ATR) | 5.22 | 0.53 |
| MACD | -0.65 | 0.18 |
| Stochastic Oscillator | 33.42 | 71.35 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About SRAD Sportradar Group AG
Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.